Skip to content


  • Article selection
  • Open Access

Articles selected in February 2004

Breast Cancer Research20046:E12

  • Published:

Authors’ Affiliations

Molecular Medicine Unit, University of Leeds, St James's University Hospital, Leeds, LS9 7TF, UK


  1. Wang LH, Yang XY, Zhang X, Mihalic K, Fan YX, Xiao W, Howard OM, Appella E, Maynard AT, Farrar WL: Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor. Nat Med. 2004, 10: 40-47.View ArticlePubMedGoogle Scholar
  2. Santen RJ, Song RX, Zhang Z, Yue W, Kumar R: Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clin Cancer Res. 2004, 10: 337-345.View ArticleGoogle Scholar
  3. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM: Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res. 2004, 10: 346-354.View ArticleGoogle Scholar
  4. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA: Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA. 2004, 101: 1566-1571.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Hoffmann J, Bohlmann R, Heinrich N, Hofmeister H, Kroll J, Kunzer H, Lichtner RB, Nishino Y, Parczyk K, Sauer G, Gieschen H, Ulbrich HF, Schneider MR: Characterization of New Estrogen Receptor Destabilizing Compounds: Effects on Estrogen-Sensitive and Tamoxifen-Resistant Breast Cancer. J Natl Cancer Inst. 2004, 96: 210-218.View ArticlePubMedGoogle Scholar
  6. Holmberg L, Anderson H, for the HABITS steering and data monitoring committees: HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. The Lancet. 2004, 363: 453-455.View ArticleGoogle Scholar
  7. Balasenthil S, Sahin AA, Barnes CJ, Wang RA, Pestell RG, Vadlamudi RK, Kumar R: p21-activated Kinase-1 Signaling Mediates Cyclin D1 Expression in Mammary Epithelial and Cancer Cells. J Biol Chem. 2004, 279: 1422-1428.View ArticlePubMedGoogle Scholar
  8. Reiter R, Oh AS, Wellstein A, Riegel AT: Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta 3 on estrogenic ligands with different intrinsic activity. Oncogene. 2004, 23: 403-409.View ArticlePubMedGoogle Scholar


© The Author(s) 2004